Skip to Content

Zembrace SymTouch Approval History

FDA Approved: Yes (First approved January 28, 2016)
Brand name: Zembrace SymTouch
Generic name: sumatriptan
Dosage form: Injection
Company: Dr. Reddy's Laboratories, Inc.
Treatment for: Migraine

Zembrace SymTouch (sumatriptan) is a selective 5-HT1B/ID receptor agonist in a prefilled, ready-to-use, single-dose disposable autoinjector for the treatment of acute migraine episodes, with or without aura.

Development History and FDA Approval Process for Zembrace SymTouch

DateArticle
Jan 29, 2016Approval Dr. Reddy’s Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide